Teva Pharmaceutical (TEVA) and Alvotech (ALVO) said Monday that Selarsdi has been approved by the US Food and Drug administration as interchangeable with the reference biologic Stelara.
Selarsdi, a human monoclonal antibody that selectively targets the p40 protein, is now interchangeable in all presentations of Stelara, which includes the treatment of psoriatic arthritis and plaque psoriasis, as well as Crohn's disease, and ulcerative colitis, the two companies said.
Teva shares were more than 7% higher in premarket trading, while Alvotech shares rose by nearly 2%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.